Jakarta, August 20. - The Rmol.id newspaper, in Indonesian language, published today that Cuba will soon begin clinical trials of its candidate vaccine, “Sovereign 01”, developed by the Finlay Vaccine Institute.
The article refers to the scheduling of clinical trials, the approval that the study already got from the regulatory authority, the Center for State Control of the Quality of Medicines (CEDMED), as well as published information from the Cuban Public Registry of Clinical Trials, which ensures that the process will be randomized, controlled, adaptive and multicenter, in order to evaluate the safety and immunogenicity of the candidate in a two-dose scheme.
The text also highlights that last Tuesday, August 18, the Cuban president, Miguel Díaz-Canel, exchanged with a group of scientists who work tirelessly on the Cuban vaccine against COVID-19, while placing their trust in the response national scientist and in the advances in the investigations on the vaccine candidates that is developing in Cuba for the prevention of SARS-CoV-2.
It should be noted that during the meeting, the President urged that, regardless of the progress of other nations in the search for a vaccine, it was important to achieve the Cuban one, as it would grant sovereignty to the country in the face of the pandemic in the midst of the hostile Imperial siege, as represented by the US blockade against the Island, with the aim of preventing everything that means development and progress of its own.
The Cuban vaccine is the first one in Latin America and number 30th. , in the select group of specific vaccines against Covid 19 in clinical trials worldwide, a great success of #CienciaCubana@PresidenciaCuba #VacunaCubanaCOVID19.
Embassy of Cuba in Indonesia.